Progressive Multiple Sclerosis: Latest Research, Emerging Therapies, and Clinical Trials

The Progressive MS Challenge

Primary progressive MS (PPMS) and non-active secondary progressive MS (SPMS) remain difficult to treat. In these forms, neurodegeneration dominates while inflammation becomes compartmentalized behind the blood-brain barrier, limiting the reach of conventional immunomodulatory therapies.

Active Research Avenues

1. Neuroprotection & Remyelination

  • Clemastine (antihistamine): The ReBUILD trial demonstrated modest remyelination measured by visual evoked potential latency improvement.
  • Opicinumab (anti-LINGO-1): Phase 2 results were mixed; further development paused.
  • Elezanumab (anti-RGMa): Promotes axonal growth and remyelination; Phase 2 ongoing.
  • Metformin + clemastine: Repurposing trial (CCMR One) exploring synergistic remyelination.
  • High-dose biotin: Failed Phase 3 (SPI2); not recommended.

2. Innate Immunity & Microglial Modulation

  • BTK inhibitors: Evobrutinib, tolebrutinib, fenebrutinib cross the blood-brain barrier to target microglia and B cells. Phase 3 trials in RMS and PPMS (HERCULES, PERSEUS, GEMINI).
  • S1P modulators: Siponimod (approved for SPMS/PPMS), ozanimod, ponesimod—sequester lymphocytes and may have direct CNS effects.
  • TREM2 agonists: Enhance microglial homeostatic function (preclinical).

3. Stem Cell & Cellular Therapies

  • AHSCT (autologous hematopoietic stem cell transplant): Resets the immune system; best for active inflammatory progressive MS. MIST trial: 78% NEDA at 5 years.
  • Mesenchymal stem cells (MSCs): Neurotrophic and immunomodulatory; Phase 2 trials (MESEMS, ACTIMUS) show mixed results.
  • Neural stem cells: Early phase; remyelination potential.

4. Genetic & Molecular Targets

  • ASO therapy: Targeting C9orf72 (ALS/FTD overlap), SLC1A2 (excitotoxicity).
  • Mitochondrial enhancers: Leriglitazone (PPARγ agonist), nicotinamide riboside.
  • Iron chelation: Deferiprone reduces chronic active lesions and smoldering inflammation.

5. Symptomatic & Rehab Innovations

  • Digital therapeutics: gait analysis, cognitive training apps.
  • Robotics/exoskeletons for gait training.
  • Non-invasive brain stimulation (tDCS, rTMS) for fatigue, cognition, spasticity.
  • Biomarker-guided treatment: neurofilament light (NfL), GFAP, smoldering lesions on MRI.

6. Combination Strategies

Anti-inflammatory (DMT) + neuroprotective + rehabilitation = rational polytherapy. Trials: OCTOPUS (adaptive platform), ChariotMS (cladribine + advanced SPMS).

Clinical Trial Participation

  • Essential for progress. Ask your neurologist or search ClinicalTrials.gov (condition: "Multiple Sclerosis, Progressive").
  • Expanded access programs for promising agents.

Current Standard of Care

  • PPMS: Ocrelizumab (only FDA-approved).
  • Active SPMS: Siponimod, ozanimod, ponesimod, cladribine, ocrelizumab, ofatumumab.
  • Non-active progressive: Symptom management, rehabilitation, comorbidity control, clinical trials.

Hope is grounded in science. The pipeline is richer than ever.

Multiple Sclerosis - Related Articles